COX-2 selective inhibitors: analysis of the renal effects
- 1 May 2002
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Drug Safety
- Vol. 1 (1) , 53-64
- https://doi.org/10.1517/14740338.1.1.53
Abstract
COX-2 selective inhibitors provide analgesia and blunt inflammation while also sparing the gastrointestinal tract from classic NSAID toxicity. Therapeutic effects are thought to result from inhibition of the inflammatory COX-2 isoform. Organ sparing is considered the result of preservation of homeostatic COX-1 enzyme function. Similar roles of the COX isoforms in the kidney would reduce NSAID-associated nephrotoxicity. However, human kidney tissue expresses COX-2 enzyme, suggesting a role for this isoform in maintenance of physiological renal processes. Available clinical data on the renal effects of COX-2 selective inhibitors in humans also demonstrate nephrotoxic potential.Keywords
This publication has 43 references indexed in Scilit:
- HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: A potential mechanism for protease inhibitor-induced hyperlipidemiaNature Medicine, 2001
- Antiretroviral therapy-associated hyperlipidaemia in HIV diseaseCurrent Opinion in Lipidology, 2001
- Lipodystrophy, Metabolic Disorders, and Human Immunodeficiency Virus Infection: Aquitaine Cohort, France, 1999Clinical Infectious Diseases, 2000
- Effects of Protease Inhibitors on Hyperglycemia, Hyperlipidemia, and LipodystrophyArchives of internal medicine (1960), 2000
- Serum lipid levels associated with increased risk for cardiovascular disease is associated with highly active antiretroviral therapy (HAART) in HIV-1 infectionInternational Journal of STD & AIDS, 2000
- Atherogenic Dyslipidemia in HIV-Infected Individuals Treated With Protease InhibitorsCirculation, 1999
- Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: acohort studyThe Lancet, 1999
- Hyperlipidemia under treatment with proteinase inhibitorsInfection, 1999
- Vascular complications associated with use of HIV protease inhibitorsThe Lancet, 1998
- Randomised placebo-controlled trial of ritonavir in advanced HIV-1 diseaseThe Lancet, 1998